ALERT: Due to the inclement weather across much of the country, Medtronic deliveries are currently experiencing delays and there will be longer than normal hold times on the phone. Visit www.Diabetes.Shop if you need to place an order, get a sensor or belt clip replacement, or check the status of your supply order. X

New Study on Insulin Pumps and Type 2 Diabetes

We’re really excited to announce the results from the Opt2mise trial have been published, and were presented at the American Diabetes Association Scientific Sessions a few weeks ago. This is the largest global study to evaluate and compare insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes.

Study Conclusion

The study showed MiniMed insulin pumps safely achieve better glucose control for people with type 2 diabetes requiring insulin when compared to multiple daily injections.

The Study Details

Study participants in the insulin pump therapy group received education and support throughout the trial. The global, randomized, controlled study was sponsored by Medtronic and conducted with participation from 331 people with type 2 diabetes, ranging in age from 30 to 75 years. Specific results include:

  • Those using insulin pumps demonstrated a mean reduction of A1C levels by 1.1 percent, versus only 0.4 percent for participants using multiple daily injections. (For every one percent drop in A1C, the risk of microvascular complications such as blindness, kidney failure and nerve damage can be reduced by 40 percent.)(1)
  • The people in the insulin pump therapy group experienced the A1C reduction without any episodes of severe hypoglycemia.
  • The total daily insulin dose was 20.4 percent lower with pump therapy than with injection therapy with no significant difference in body weight change between the two groups.
  • The percentage of participants in the insulin pump therapy group achieving an A1C <8 percent was twice that of the multiple daily injections group (55 percent versus 28 percent). Studies have reported that near-normal glucose control can prolong life an average of five years, and delay the onset of complications from diabetes, such as blindness, kidney failure, amputation, impotence, coma and heart disease, by an average of 15 years.(1)

The results from the OpT2mise trial are exciting and could help more people with type 2 diabetes who take insulin (that’s approximately 4.4 million people in the U.S., and 20 million people globally!).

Leave a comment to let us know what you think!

(1) Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA, November 6, 1996; 276: No.17.


– Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems.
– Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.

Medtronic Diabetes Insulin Infusion Pumps

– Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day.
– Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.

Please visit for more details.

Print This Post Print This Post
Tags: , , ,
Latest Comments
  1. Avatar Geraldine Kordes Guthrie
    • Avatar Sara Tilleskjor
  2. Avatar Nancy
    • Avatar Sara Tilleskjor
  3. Avatar Abdulhameed
  4. Avatar Ron Ponce
    • Avatar Sara Tilleskjor
  5. Avatar Kelly
    • Avatar Karrie Hawbaker
  6. Avatar Garth Malena
    • Nicole Nicole

Post A Comment

Your email address will not be published. Required fields are marked *